We are live on ! Find out more
VTYX

Ventyx Biosciences
VTYX

Delisted

VTYX was delisted on the 3rd of March, 2026.

Back to rankings

104 hedge funds and large institutions have $1.41B invested in Ventyx Biosciences in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,367% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 3

245% more capital invested

Capital invested by funds: $408M → $1.41B (+$1B)

65% more funds holding

Funds holding: 63 → 104 (+41)

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

45% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 20

11.64% more ownership

Funds ownership: 68.1% → 79.74% (+12%)

12% less call options, than puts

Call options by funds: $1.97M | Put options by funds: $2.25M

Holders
104
Holders Change
+41
Holders Change %
+65.08%
% of All Funds
1.79%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.1%
New
44
Increased
29
Reduced
20
Closed
3
Calls
$1.97M
Puts
$2.25M
Net Calls
-$277K
Net Calls Change
-$277K

Top Buyers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$38.5M
2
DGM
Darwin Global Management
Jersey
+$31M
3
RG
Redmile Group
California
+$30.2M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$23.7M
5
BC
Boxer Capital
California
+$18.8M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$23.6M
2
LGM
Logos Global Management
California
-$20.3M
3
EC
EcoR1 Capital
California
-$19.9M
4
FCM
Farallon Capital Management
California
-$19.1M
5
VC
Vivo Capital
California
-$12.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
American Century Companies
26
American Century Companies
Missouri
$10.4M -$2.76M -124,607 -29%
GPP
27
Great Point Partners
Connecticut
$9.43M -$2.64M -119,256 -31%
VA
28
VR Adviser
New York
$7.26M +$4.6M +207,925 New
SCM
29
Suvretta Capital Management
New York
$6.51M +$4.13M +186,400 New
Northern Trust
30
Northern Trust
Illinois
$6.42M +$383K +17,293 +10%
ACP
31
Acuta Capital Partners
California
$6.28M +$1.28M +58,000 +48%
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$6.03M +$3.43M +154,787 +863%
AAA
33
Affinity Asset Advisors
New York
$5.93M +$3.76M +170,000 New
Charles Schwab
34
Charles Schwab
California
$5.6M +$1.39M +62,900 +64%
HighTower Advisors
35
HighTower Advisors
Illinois
$5.33M – – –
MS
36
Maven Securities
Jersey
$5.24M +$3.32M +150,000 New
WP
37
Woodline Partners
California
$4.49M +$192K +8,663 +7%
TLP
38
Tri Locum Partners
New York
$4.36M +$2.77M +125,000 New
NCM
39
Nantahala Capital Management
Connecticut
$4.07M +$2.58M +116,633 New
IHAM
40
Integral Health Asset Management
New York
$3.49M +$2.21M +100,000 New
Two Sigma Investments
41
Two Sigma Investments
New York
$3.19M +$2.02M +91,395 New
EI
42
EAM Investors
California
$2.91M +$1.84M +83,238 New
Morgan Stanley
43
Morgan Stanley
New York
$2.89M +$1.41M +63,512 +330%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$2.81M +$668K +30,153 +60%
EGI
45
EAM Global Investors
California
$2.52M +$1.6M +72,217 New
FCM
46
Farallon Capital Management
California
$2.44M -$19.1M -860,648 -92%
N
47
Nuveen
North Carolina
$2.41M -$9.56K -432 -0.6%
CCM
48
CAAS Capital Management
New York
$2.03M +$1.33M +60,000 New
BC
49
Birchview Capital
Vermont
$1.57M +$266K +12,000 +36%
AR
50
Advisory Research
Illinois
$1.11M +$702K +31,726 New
1
2
3 4 5

VTYX Hedge Fund Activity: Q3 2022 in Review

104 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q3 2022, worth a combined $1.41B — up 245% from $408M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new VTYX positions and 3 closed out — a net gain of 41 holders — while 29 added to existing stakes and 20 trimmed.

The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $38.5M. The largest seller was OrbiMed, cutting an estimated $23.6M.

  • 104 institutional investors held Ventyx Biosciences (VTYX) as of Q3 2022, up from 63 in Q2 2022.
  • Funds reported $1.41B of Ventyx Biosciences stock for Q3 2022, up 245% quarter-over-quarter.
  • 44 funds opened new Ventyx Biosciences positions in Q3 2022 and 3 closed out, a net change of +41 holders.
  • The largest Ventyx Biosciences buyer in Q3 2022 was Lord, Abbett & Co, an estimated $38.5M added.
  • The largest Ventyx Biosciences seller in Q3 2022 was OrbiMed, an estimated $23.6M sold.

Based on aggregated 13F filings for Q3 2022.